VENTURE (12+ years), TRAVERSE OLE (12+ years)

86% of patients reduced or eliminated their OCS dose at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs 68% with placebo + SOC (n=107) (No biomarker requirement, ITT population, VENTURE).¹³

A 70% significant reduction in OCS dose (median 100%) from baseline was observed at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) (95% CI: 60%, 80%) vs 42% (median 50%) with placebo + SOC (n=107) (primary endpoint).¹

89% reduction in OCS dose at Week 96 (TRAVERSE OLE).¹⁴

From PSBL for patients who received DUPIXENT 300 mg Q2W + SOC in the parent study and continued on DUPIXENT during the open-label extension study (n=19).^14,d

By Week 96 in TRAVERSE OLE, a 79% reduction in exacerbations and a 250 mL improvement in lung function from PSBL were observed.^9,14,e

In addition, 79% of patients from VENTURE eliminated their OCS dose at Week 96 in TRAVERSE OLE (secondary endpoint).^9,14

• A gradual increase in the number of patients eliminating their OCS dose was observed from 53.3% at Week 0 (n=48) to 59.6% at Week 48 (n=34) to 78.9% at Week 96 (n=15) in the DUPIXENT/DUPIXENT group^f

TRAVERSE OLE results are descriptive. Definitive conclusions cannot be made.

Data were not multiplicity controlled, and there are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attritions of nonresponders.